# HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure

> **NCT05135364** · PHASE2 · UNKNOWN · sponsor: **Yue Han** · enrollment: 48 (estimated)

## Conditions studied

- Unresectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** HAIC
- **DRUG:** TKI

## Key facts

- **NCT ID:** NCT05135364
- **Lead sponsor:** Yue Han
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-05
- **Primary completion:** 2022-10-05
- **Final completion:** 2024-12-05
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2021-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05135364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05135364, "HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05135364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*